Literature DB >> 3227231

Studies on the effect of short term, high dose praziquantel treatment against protoscoleces of ovine and equine Echinococcus granulosus within the cyst, and in vitro.

K S Richards1, E M Riley, D H Taylor, D L Morris.   

Abstract

Protoscoleces of Echinococcus granulosus were subjected to high concentrations of praziquantel (10-1000 micrograms/ml medium or cyst fluid) for a short, 10 min duration in vitro or in situ within cysts. Drug efficacy was then monitored either by in vitro culture in drug-free medium and/or by passage into rodents. The in vitro test of effectiveness suggested that ovine-derived protoscoleces were more sensitive than those of equine origin, and that the in vitro method of treatment was more successful than that performed in situ. However, the subsequent passage of treated protoscoleces, whether immediately after in situ or in vitro exposure or after culture in drug-free medium, indicated that the in situ administration was as effective as the in vitro treatment. Both methods reduced cyst burdens in rodents to 9-15% of control infections.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3227231

Source DB:  PubMed          Journal:  Trop Med Parasitol        ISSN: 0177-2392


  4 in total

Review 1.  Anthelminthic agents: some recent developments and their clinical application.

Authors:  G C Cook
Journal:  Postgrad Med J       Date:  1991-01       Impact factor: 2.401

2.  Echinococcus of the liver.

Authors:  D L Morris
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

3.  A combined medical and surgical approach to hydatid disease: 12 years' experience at the Hospital for Tropical Diseases, London.

Authors:  H M Ayles; E L Corbett; I Taylor; A G A Cowie; J Bligh; K Walmsley; A D M Bryceson
Journal:  Ann R Coll Surg Engl       Date:  2002-03       Impact factor: 1.891

Review 4.  Biological, epidemiological, and clinical aspects of echinococcosis, a zoonosis of increasing concern.

Authors:  Johannes Eckert; Peter Deplazes
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.